NEWS

03/18/2008 Cytopia Limited (ASX:CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease. Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential… Read More »CYTOPIA NOMINATES JAK2 CLINICAL CANDIDATE FOR MYELOPROLIFERATIVE DISORDERS

Wilmington, Del. — (Business Wire) — Incyte Corporation (Nasdaq: INCY) today reported full year and fourth quarter 2007 financial results, and announced its 2008 financial guidance and key objectives and plans for its rapidly expanding clinical pipeline. Paul A. Friedman, M.D., President and CEO of Incyte, state, “Over the past year, we’ve worked intensively to… Read More »INCYTE REPORTS PROGRESS IN MULTIPLE CLINICAL PROGRAMS AND EXPANDS JAK INHIBITOR PROGRAM

San Diego, CA – January 31, 2008 – TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases. The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia… Read More »TARGEGEN ANNOUNCES INITIATION OF CLINICAL TRIAL OF JAK2 INHIBITOR TG101348 IN MYELOPROLIFERATIVE DISEASE PATIENTS

MELBOURNE, Australia, Jan. 30 /PRNewswire/ — Australian and New York based company Cytopia Limited announced today that its lead JAK2 inhibitor compound CYT387 has demonstrated potent activity in cells isolated from patients with myeloproliferative disorders (MPDs). MPDs are a series of diseases where there is over-production of particular cells within the blood stream. One of… Read More »JAK2 INHIBITOR SHOWS POTENT ACTIVITY IN CELLS FROM MPD PATIENTS

12/10/2007 2:06:40 PM Monday afternoon, Exelixis, Inc. (EXEL), a developer of therapies for the treatment of cancer and other serious diseases, announced data from an ongoing Phase 1 trial of XL019 to treat patients with myelofibrosis, a myeloproliferative disorder, or MPD. The primary objective of the trial is to determine the safety and tolerability of… Read More »EXELIXIS REPORTS DATA FROM ONGOING PHASE 1 STUDY OF XL019 TO TREAT MYELOFIBROSIS – UPDATE

By Mike Nagle 24/05/2007 – At a time when pharma productivity is declining, anticancer specialists Exelixis has started more Phase I clinical trials this year than any other company. The US biotech has today filed an Investigational New Drug (IND) application to US regulators at the Food and Drug Administration (FDA). It is the company’s… Read More »EXELIXIS WINNING PHASE I RACE

Thursday October 19, 7:25 pm ET Approvals Represent First Time a Regulatory Authority has Simultaneously Approved One Targeted Medicine for Five DisordersNow Approved for the Solid Tumor Cancer, Dermatofibrosarcoma ProtuberansUS Approval Also Granted for Treatment of Four Blood Diseases:Multiple Approvals in Only Five Years Highlight new Approach of Developing Treatments Based on Common Molecular Pathways… Read More »GLEEVEC(R) APPROVED IN THE US FOR FIVE RARE LIFE-THREATENING DISORDERS WITH LIMITED TREATMENT OPTIONS

Thursday, October 19, 2006 · Last updated 3:30 p.m. PTTHE ASSOCIATED PRESS WASHINGTON — A Novartis AG cancer drug has won expanded federal approval to treat five rare and potentially life-threatening diseases, the company said Thursday. Gleevec, also called imatinib mesylate, may now be prescribed to treat dermatofibrosarcoma protuberans tumors, as well as four blood… Read More »NOVARTIS DRUG

Drs. Verstovsek and Rafandi present data on Incyte’s JAK2 Inhibitor, INCB018424, currently being tested in MPD patients Dr. Tefferi presents research on JAK2 germline and survival in MF patients Favorable review of Cytopia by Mayo’s IRB and FDA for their JAK2 Inhibitor CYT387 trial now under way SBIO to present data on their JAK2 Inhibitor… Read More »ASH NEWS ON MYELOPROLIFERATIVE DISORDERS

Each year the American Society of Hematology (ASH) hosts their annual convention, where researchers, doctors and organizations such as the MPD Foundation gather to discuss the ever changing world of blood disorders and learn about the progress of research. The MPD Foundation is pleased to once again host a booth at this year’s ASH convention.… Read More »AMERICAN SOCIETY OF HEMATOLOGY CONVENTION 2009